The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network Approach

SECONDARY PARTICIPANTS INCLUSION AND EXCLUSION CRITERIA Study INCLUSION criteria for primary participants are as follows: * Current PWID (i.e., injected any drug at least once during the previous six months); * Evidence of chronic HCV infection (detectable plasma HCV RNA viral load above 1000 IU/ml on two occasions ≥ 6 months apart) * Willing and able to provide written informed consent. Subjects must have the following laboratory parameters at screening: * ALT \<10 times the upper limit of normal (ULN) * AST \<10 times ULN * Haemoglobin ≥12g/dL for males, ≥11g/dL for female subjects * INR ≤1.5 times ULN unless is stable on an anticoagulant regimen affecting INR * Albumin ≥3g/dL * Direct bilirubin ≤1.5 times ULN * Creatinine clearance (CLcr) ≥60mL/min, as calculated by the Cockcroft-Gault Equation. EXCLUSION criteria for all primary participants are as follows: * Testing positive for HIV * History of, or current, decompensated liver disease * Testing positive for HBsAg * HCC * Women who are pregnant or breastfeeding, or men with female partners who are pregnant at screening or baseline, or who were pregnant in the six months prior to screening * Already enrolled in the TAP Study as a secondary participant (see below) * Evidence of any condition, therapy, laboratory abnormality or other circumstance (current or prior) that may confound the study's results, or interfere with participation for the full duration of the study, such that it is not in the best interest of the …